<DOC>
	<DOCNO>NCT00372944</DOCNO>
	<brief_summary>The purpose study assess efficacy safety AZD6244 ( ARRY-142886 ) versus capecitabine patient advance metastatic pancreatic cancer fail first-line therapy gemcitabine . Following baseline assessment , minimum 64 patient approximately 5-6 center US treat either AZD6244 capecitabine . Treatment continue long patient receive clinical benefit . The status patient check ( whether still take treatment ) approximately 3 month last patient enter study .</brief_summary>
	<brief_title>AZD6244 vs. Capecitabine ( XelodaÂ® ) Patients With Advanced Metastatic Pancreatic Cancer , Who Have Failed First Line Gemcitabine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Confirmed pancreatic cancer Have fail first line gemcitabine therapy Previous therapy EGFR inhibitor , MEK inhibitor capecitabine . Any recent surgery , unhealed surgical incision severe condition uncontrolled cardiac disease chronic gastrointestinal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>advanced pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>AZD6244</keyword>
</DOC>